当前位置:
X-MOL 学术
›
Tetrahedron Lett.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
An alternative synthesis of the non-small cell lung carcinoma drug afatinib
Tetrahedron Letters ( IF 1.5 ) Pub Date : 2018-10-15 , DOI: 10.1016/j.tetlet.2018.10.026 Tatjana Kovacevic , Milan Mesic , Amir Avdagic , Miroslav Zegarac
中文翻译:
非小细胞肺癌药物阿法替尼的另一种合成方法
更新日期:2018-10-15
Tetrahedron Letters ( IF 1.5 ) Pub Date : 2018-10-15 , DOI: 10.1016/j.tetlet.2018.10.026 Tatjana Kovacevic , Milan Mesic , Amir Avdagic , Miroslav Zegarac
Afatinib (BIBW2992) is the anticancer drug developed by Boehringer Ingelheim. This work is reporting the synthesis of the afatinib using a new route by Ullmann-Goldberg reaction from corresponding 4-anilinoquinazoline iodide as the last step in the synthesis. This route was not described previously and it could be used for synthesis of afatinib analogues.
中文翻译:
非小细胞肺癌药物阿法替尼的另一种合成方法
阿法替尼(BIBW2992)是勃林格殷格翰公司开发的抗癌药物。这项工作报告了通过Ullmann-Goldberg反应从相应的4-苯胺基喹唑啉碘化物通过Ullmann-Goldberg反应的新路线合成afatinib的最后一步。该路线先前未作描述,可用于合成阿法替尼类似物。